Correction: Advances in Therapy (2026) 43:2852–2870 https://doi.org/10.1007/s12325-026-03612-5
The introduction of the original article contained statements referencing two retracted studies [15, 16]. These statements have been revised to more closely reflect the specific wording of the retraction notices and to better reflect the limitations of the cited literature. The corrected text reads:
“Lower-dose regimens such as very-low-dose naltrexone (VLDN; 0.1–0.5 mg) and ultra-low-dose naltrexone (ULDN; <1 µg) have attracted interest, but the mechanistic evidence base remains limited. No specific mechanisms have been demonstrated for VLDN, and some of the key mechanistic studies for ULDN have been retracted due to concerns about the integrity and reliability of data presented [15, 16]. Claims about distinct mechanisms of action at these very-low and ultra-low doses should therefore be interpreted in light of these considerations.”
This amendment is intended to improve the precision of the wording in relation to the literature and retraction notices. It does not affect the conclusions of the article.
The original article has been corrected.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.